1	Systematic review of genotype-stratified treatment for monogenic insulin resistance
2	
3	Robert K. Semple ^{1,2} , Kashyap A. Patel ^{3,4} , Sungyoung Auh ⁵ , ADA/EASD PMDI ⁶ , Rebecca J. Brown ⁷
4	
5	Affiliations
6 7 9 10 11 12 13 14 15 16 17	 ¹ Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK ² MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK ³ Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK. ⁴ Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. ⁵ Office of the Clinical Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA ⁶ American Diabetes Initiative ⁷ National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health. Bethesda, MD, USA.
19	Correspondence

- 20 Rebecca J. Brown, MD, MHSc
- 21 Building 10-CRC, Room 6-5942
- 22 10 Center Drive
- 23 Bethesda, MD 20892
- 24 Email: brownrebecca@niddk.nih.gov
- 25 Voicemail: 301-594-0609
- 26 Fax: 301-480-0365
- 27

28 Keywords

- 29 Precision Medicine, Diabetes, Genetics, Insulin Resistance, Lipodystrophy, Insulin Receptor,
- 30 Metreleptin, Leptin, thiazolidinediones, Insulin-like growth factor-1
- 31

32 Running Title

- 33 Precision Treatment of Monogenic Insulin Resistance
- 34
- 35 Word counts Abstract: 297 words; Main Text: 3,501 words

36 Abstract

37

Objective: To assess the effects of pharmacologic and/or surgical interventions in monogenic insulin
 resistance (IR), stratified by genetic aetiology.

40 **Design:** Systematic review.

41 Data sources: PubMed, MEDLINE and Embase, from 1 January 1987 to 23 June 2021.

42 **Review methods:** Studies reporting individual-level effects of pharmacologic and/or surgical 43 interventions in monogenic IR were eligible. Individual subject data were extracted and duplicate 44 data removed. Outcomes were analyzed for each affected gene and intervention, and in aggregate 45 for partial, generalised and all lipodystrophy.

46 Results: 10 non-randomised experimental studies, 8 case series, and 21 single case reports met 47 inclusion criteria, all rated as having moderate or serious risk of bias. Metreleptin was associated 48 with lower triglycerides and hemoglobin A1c in aggregated lipodystrophy (n=111), in partial 49 lipodystrophy (n=71) and generalised lipodystrophy (n=41)), and in LMNA, PPARG, AGPAT2 or BSCL2 50 subgroups (n=72,13,21 and 21 respectively). Body Mass Index (BMI) was lower after treatment in 51 partial and generalised lipodystrophy overall, and in LMNA or BSCL2, but not PPARG or AGPAT2 52 subgroups. Thiazolidinedione use was associated with improved hemoglobin A1c and triglycerides in 53 aggregated lipodystrophy (n=13), improved hemoglobin A1c only in the PPARG subgroup (n=5), and 54 improved triglycerides only in the LMNA subgroup (n=7). In INSR-related IR, use of rhIGF-1, alone or 55 with IGFBP3, was associated with improved hemoglobin A1c (n=15). The small size or absence of all 56 other genotype-treatment combinations precluded firm conclusions.

57 **Conclusions:** The evidence guiding genotype-specific treatment of monogenic IR is of low to very low 58 quality. Metreleptin and Thiazolidinediones appear to have beneficial metabolic effects in 59 lipodystrophy, and rhIGF-1 appears to lower hemoglobin A1c in INSR-related IR. For other 60 interventions there is insufficient evidence to assess efficacy and risks either in aggregated 61 lipodystrophy or in genetic subgroups. There is a pressing need to improve the evidence base for 62 management of monogenic IR.

63

64 Introduction

Diabetes caused by single gene changes is highly heterogeneous in molecular aetiopathogenesis. It may be grouped into disorders featuring primary failure of insulin secretion, and disorders in which insulin resistance (IR), often severe, predates secondary failure of insulin secretion and diabetes. Monogenic IR is itself heterogeneous, encompassing primary lipodystrophy syndromes, primary disorders of insulin signalling, and a group of conditions in which severe IR is part of a more complex developmental syndrome 1.

72 Monogenic IR is rare but underdiagnosed. The commonest subgroup is formed by genetic lipodystrophy syndromes ^{2,3}. 73 Recent analysis of a large clinical care cohort 74 unselected for metabolic disease suggested a clinical prevalence of lipodystrophy of around 1 in 20,000, with a prevalence of plausible lipodystrophy-causing genetic variants of around 75 1 in 7,000 4 . Monogenic IR is important to recognise, because affected patients are at risk 76 77 not only of micro- and macrovascular complications of diabetes, but also of complications 78 such as dyslipidemia, pancreatitis, and steatohepatitis, especially in lipodystrophy 79 syndromes⁵. Non-metabolic complications specific to individual gene defects may also 80 occur, including hypertrophic cardiomyopathy and other manifestations of soft tissue overgrowth³. Diabetes is also commonly the sentinel presentation of a multisystem 81 82 disorder, and recognition of complex syndromes in a diabetes clinic may trigger definitive 83 diagnostic testing.

The only therapy licensed specifically for monogenic IR is recombinant human methionyl leptin (metreleptin), with licensed indications encompassing a subset of patients with lipodystrophy and inadequate metabolic control ^{6,7}. The current license in the USA is

87 restricted to generalised lipodystrophy, but in Europe it extends to some patients with 88 partial lipodystrophy. A significant proportion of the body of evidence considered in 89 licensing addressed patients ascertained by presence of clinical lipodystrophy, and the role 90 of genetic stratification in precision treatment of lipodystrophy has not been systematically 91 addressed. Many other medications and other treatment options are also widely used in 92 monogenic IR, although not licensed for that specific subgroup. Such use draws on the 93 evidence base and treatment algorithms developed for type 2 diabetes. Several forms of 94 monogenic IR have molecular and/or clinical attributes that suggest potential precision 95 approaches to treatment.

96 We sought now to undertake a systematic review of the current evidence guiding 97 treatment of monogenic IR stratified by genetic aetiology, to assess evidence for differential 98 responses to currently used therapies, to establish gaps in evidence, and to inform future 99 studies. This systematic review is written on behalf of the American Diabetes Association 100 (ADA)/European Association for the Study of Diabetes (EASD) Precision Medicine in Diabetes 101 *Initiative* (PMDI) as part of a comprehensive evidence evaluation in support of the 2nd International Consensus Report on Precision Diabetes Medicine [Tobias et al, Nat Med]. 102 103 The PMDI was established in 2018 by the ADA in partnership with the EASD to address the burgeoning need for better diabetes prevention and care through precision medicine⁸. 104

105

106 Methods

107 Inclusion Criteria and Search Methodology

108 To assess treatment of severe IR of known monogenic aetiology, with or without 109 diabetes mellitus, including generalised and partial lipodystrophy and genetic disorders of

the insulin receptor, we developed, registered and followed a protocol for a systematic review (Prospero ID <u>CRD42021265365</u>; registered July 21, 2021)⁹. The study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Filtering and selection of studies for data extraction were recorded using the Covidence platform (https://www.covidence.org, Melbourne, Australia).

115 We searched PubMed, MEDLINE and Embase from 1987 (the year before 116 identification of the first monogenic aetiology of IR) to June 23, 2021 for potentially relevant 117 human studies in English. We used broad search terms designed to capture the 118 heterogeneity of monogenic IR and its treatments. We searched for studies addressing 1. 119 Severe IR due to variant(s) in a single gene OR 2. Congenital generalised or familial partial 120 lipodystrophy due to variant(s) in a single gene. We selected only studies that reported a 121 treatment term, including but not limited to mention of 1. Thiazolidinediones (TZD), 2. 122 Metreleptin, 3. SGLT2 inhibitors, 4. GLP-1 analogues, 5. Bariatric surgery (all types), 6. 123 Recombinant human IGF-1 or IGF-1/IGFBP3 composite, 7. U-500 insulin. No interventions 124 were excluded in the primary search. In addition to the automated search, we hand 125 searched reference lists of relevant review articles. Given the rarity of monogenic IR, no 126 study types were excluded in the initial search. We ultimately considered experimental 127 studies, case reports, and case series. The full search strategy is described in Supplemental 128 Table 1.

Study selection for data extraction was performed in two phases, namely primary screening of title and abstract, then full text review of potentially eligible articles. Two authors independently evaluated eligibility, with discrepancies resolved by a third investigator. We excluded publications without original data, such as reviews, editorials, and comments, and those solely addressing severe IR or lipodystrophy of unknown or known

non-monogenic aetiology, including HIV-related or other acquired lipodystrophies, or
autoimmune insulin receptoropathy (Type B insulin resistance). Studies in which no clear
categorical or numerical outcome of an intervention was reported, or in which interventions
were administered for less than 28 days were also excluded.

138 Data extraction and outcome assessments

One author extracted data from each eligible study using data extraction sheets. Data from each study was verified by all 3 authors to reach consensus. Data were extracted from text, tables, or figures. Study investigators were contacted for pertinent unreported data or additional details where possible, most commonly genetic aetiology of insulin resistance in reported patients, and outcome data.

144 Data extracted for each study included first author, publication year, country, details 145 of intervention, duration of follow-up, study design, and number of participants. Subject-146 level data were extracted for outcomes of interest, including sex, genetic cause of severe 147 insulin resistance (gene name, mono- vs biallelic INSR pathogenic variant), phenotypic 148 details of severe IR/lipodystrophic subtype (generalised vs partial lipodystrophy; associated 149 syndromic features). Subject level outcome data for were extracted prior to and after the 150 longest-reported exposure to the intervention of interest for hemoglobin A1c (A1c), body 151 mass index, serum triglyceride, ALT, or AST concentration, any index of liver size or lipid 152 content, and total daily insulin dose. Potential adverse effects of interventions were 153 recorded, including urinary tract infection, genital candidiasis, hypoglycemia, excessive 154 weight loss, pancreatitis, soft tissue overgrowth, and tumor formation.

155

156 Risk of bias and certainty of evidence assessment

157	Quality of extracted case reports and case series was assessed using NIH Study
158	Quality Assessment Tools ¹⁰ . Grading of overall evidence for specific research questions was
159	undertaken as detailed in 11 .

160

161 Data synthesis and analysis

162 Extracted data were managed using Covidence and analysed with SAS version 9.4. 163 Pooled analysis was undertaken for all combinations of genotype and intervention for which 164 sufficient numbers were reported, as well as for aggregated lipodystrophies, and 165 generalized and partial subgroups of lipodystrophy. Generalized Estimating Equation 166 models were used with time as a fixed factor and study as a random factor to examine 167 treatment effects. Serum triglyceride concentrations were analyzed with and without log 168 transformation. Data were summarized using estimated least-squared means with 169 corresponding 95% confidence intervals.

170

171 Results

172 Identification of eligible studies

173 Initial searching identified 2,933 studies, to which 109 were added from the 174 bibliography of a recent comprehensive review of monogenic lipodystrophy ². 248 articles 175 remained after screening of titles and abstracts, and 42 after full text screening (Figure 1).

176

177 Included studies addressed limited interventions and most had a high risk of bias

The 42 studies analysed, and assessment of their quality are summarised in Table 1 and detailed in Supplemental Table 2. Study quality was assessed as being fair in 15 cases and poor in 27 cases, including all case reports. This was primarily due to high risk of bias,

181 particularly related to lack of control group for all studies. Three of the 42 studies included 182 in further analysis included only individuals already described in other reports and were 183 discarded, leaving 39 studies for final analysis. These comprised 10 non-controlled 184 experimental studies, 8 case series and 21 individual case reports (Table 1). No controlled 185 trials were found. Individuals reported in the studies included 90 with partial lipodystrophy 186 (72 due to LMNA mutation and 15 due to PPARG mutation), 42 with generalized 187 lipodystrophy (21 AGPAT2, 21 BSCL2, 2 LMNA), and 17 with IR due to INSR mutation(s). 188 Among the interventions described, only the responses to metreleptin (111 recipients), 189 thiazolidinediones (13 recipients) and rhIGF-1 (alone or as a composite with IGFBP3) (15 190 recipients) were described in more than 5 cases (Table 1). This meant that for the large preponderance of possible genotype-treatment combinations no specific data were 191 192 recovered (Supplemental Table 3). Full outcome data extracted are summarised in 193 Supplemental Table 4, and subject-level data are shown in Supplemental Figures 1 through 194 8.

195

196 Metreleptin treatment was associated with improved metabolic control in lipodystrophy

197 In our registered systematic review plan we posed several subquestions about 198 treatment of monogenic IR subtypes that we felt were tractable. The first related to the 199 risks and benefits (assessed by side effects, A1c, serum triglyceride concentration, body 200 mass index (BMI), and indices of fatty liver) of metreleptin in patients with different 201 monogenic subtypes of lipodystrophy. The response to metreleptin was described in 111 people (71 with partial lipodystrophy, 40 with generalized lipodystrophy) ¹²⁻²². Metreleptin 202 203 was administered for 19±20 months (median 12, range 1-108) and was associated with 204 lowering of A1c in aggregated lipodystrophy, in generalized and partial subgroups, and in all

205 genetic subgroups for whom sufficient patients were reported, namely those with LMNA, 206 PPARG, AGPAT2 and BSCL2 mutations (0.5 to 1.5% least square mean reduction) (Level 3 207 evidence, Supplemental Table 4, Figure 2). Metreleptin treatment was also associated with 208 lowering of serum triglyceride concentration in aggregated lipodystrophy, in generalized 209 and partial subgroups, and in those with LMNA, PPARG, AGPAT2 and BSCL2 mutations (92 to 210 1760 mg/dL least square mean reduction for analyses of untransformed data) (Level 3 211 evidence, Supplemental Table 4, Figure 2). BMI was lower after treatment in aggregated lipodystrophy, in generalized and partial subgroups, and in those with LMNA or BSCL2 212 213 mutations, but not PPARG or AGPAT2 mutations (Level 3 evidence, Supplemental Table 4, 214 Figure 2). Liver outcomes reported were too heterogeneous to analyse in aggregate. Only a 215 single adverse event, namely hypoglycemia, was reported.

216

217 Thiazolidinedione treatment showed variable efficacy in limited studies

218 We next addressed the evidence of risks and benefits of thizolidinediones (TZDs) in 219 patients with lipodystrophy. We were specifically interested in any evidence of a greater or 220 lesser response in partial lipodystrophy caused by PPARG variants than in other 221 lipodystrophy subtypes, as TZDs are potent ligands for the gene product of the PPARG gene, 222 the master regulator of adipocyte differentiation. The response to TZDs was described in only 13 people, however (12 FPLD, 1 CGL) ²³⁻³². TZDs were administered for 29±28 months 223 224 (median 24, range 2-96). TZD use was associated with improved A1c in aggregated 225 lipodystrophy (least square mean reduction 2.2%) and in PPARG-related but not LMNA-226 related partial lipodystrophy (Level 4 evidence, Supplemental Table 4, Figure 3). Serum 227 triglyceride concentration decreased in aggregated lipodystrophy and in those with LMNA-

228 related but not *PPARG*-related partial lipodystrophy (Level 4 evidence, Supplemental Table

4, Figure 3). No adverse events were reported.

230

231 rhIGF-1 treatment in INSR-related IR was associated with improvement in A1c

232 Our last specific question related to the risks (e.g. tumors, hypoglycemia, cardiac 233 hypertrophy, other soft tissue overgrowth) and benefits (assessed by A1c) of recombinant 234 human IGF-1 (rhIGF-1) or IGF-1/IGFBP3 composite in patients with pathogenic INSR variants. 235 The response to rhIGF-1 was described in 15 people with pathogenic INSR variants for a mean of 50±86 months (median 12, range 1-288)³³⁻⁴². In *INSR*-related IR, we found that use 236 237 of rhIGF-1, alone or as a composite with IGFBP3, was associated with improvement in A1c, 238 and this was true also in subgroups with monoallelic and biallelic variants (1 to 2% least 239 square mean reduction, Level 4 evidence, Supplemental Table 4, Figure 4). One instance of 240 increased soft tissue overgrowth and two episodes of hypoglycemia was reported.

241

242 Many questions about genotype-stratified treatment were not addressed

While many other interesting and clinically relevant questions arise about other potential genotype-specific responses to therapy in monogenic IR, the small size or absence of other genotype by treatment groups precluded the drawing of conclusions about risks and benefits, including for very widely used medications such as metformin ^{25,43-45}, newer agents commonly used in type 2 diabetes including SGLT2 inhibitors ^{46,47} and GLP1 agonists, and non pharmacologic interventions such as bariatric surgery ⁴⁸⁻⁵⁰.

249

250 Discussion

Thirty-five years since INSR mutations were identified in extreme IR ^{51,52}, and 23 251 years since the first monogenic cause of lipodystrophy was reported ⁵³, many different 252 forms of monogenic IR are known $^{1-3,54}$. These are associated with substantial early 253 254 morbidity and mortality, ranging from death in infancy to accelerated complications of 255 diabetes and fatty liver disease in adulthood, depending on the genetic subtype. Several 256 opportunities for genotype-guided, targeted treatment are suggested by the causal genes, 257 and so we set out to review the current evidence guiding treatment of monogenic IR 258 stratified by genetic aetiology. We found a paucity of high-quality evidence (all level 3 to 4). 259 No controlled trials of any intervention were identified, and there was substantial 260 heterogeneity of study populations and intervention regimens, even for the same 261 interventional agent.

262 The evidence which we did find, from a small number of uncontrolled experimental 263 studies, augmented by case series and numerous case reports, suggest that metreleptin 264 offers metabolic benefits across different lipodystrophy subtypes, in keeping with its 265 licensing for use in some patients with lipodystrophy in both Europe and the USA. Notably, 266 the evidence base considered by licensing authorities was larger than the one we present, 267 including many studies of phenotypically ascertained lipodystrophy that included acquired 268 or idiopathic disease. In contrast we have addressed solely individuals with lipodystrophy 269 caused by variation in a single gene. The limited data we identified do not clearly support 270 differential effects among different monogenic lipodystrophy subgroups, but for many 271 subtypes numbers reported are very small. Moreover although responses appear 272 comparable for partial and generalised lipodystrophy, this is highly likely to reflect selection 273 bias in studies of partial lipodystrophy towards those with more severe metabolic 274 complications and lower baseline serum leptin concentrations.

275 A clear opportunity for precision diabetes therapy in monogenic IR is offered by the 276 IR and lipodystrophy caused by mutations in *PPARG*, which encodes the target for thiazolidinediones (TZDs) such as pioglitazone ^{55,56}. PPARG is a nuclear receptor that serves 277 278 as the master transcriptional driver of adipocyte differentiation, and so as soon as PPARG 279 mutations were identified to cause severe IR, there was interest in the potential of TZDs as 280 specific treatments. Although we found small scale evidence supporting greater A1c 281 reduction with TZDs in PPARG vs LMNA-related lipodystrophy, only 5 patients with PPARG-282 related lipodystrophy in whom TZD effects were clearly described were reported, and 283 responses were inconsistent. Thus, it remains unclear whether people with IR due to PPARG 284 variants are more or indeed less sensitive to TZDs than people with other forms of lipodystrophy. Loss-of-function PPARG mutations are the second commonest cause of 285 familial partial lipodystrophy², and the function of coding missense variants in *PPARG* has 286 been assayed systematically to accelerate genetic diagnosis ⁵⁷, so the opportunity to test 287 288 genotype-related therapy in *PPARG*-related IR seems particularly tractable in future.

289 Other obvious questions about targeted treatment of monogenic, lipodystrophic IR 290 are not addressed by current evidence. Important examples relate to the risks and benefits 291 of treatments used in type 2 diabetes such as GLP-1 agonists and SGLT2 inhibitors. It is 292 rational to suppose that these medications, which decrease weight as well as improving 293 glycaemia in those with raised BMI and diabetes, may also be efficacious in lipodystrophy 294 even where BMI is normal or only slightly raised. This is because in both situations adipose 295 storage capacity is exceeded, leading to "fat failure". It is the offloading of overloaded 296 adipose tissue, rather than the baseline BMI/adipose mass, which underlies the efficacy of 297 therapy. However GLP-1 agonists are contraindicated in those with prior pancreatitis, while 298 SGLT2 inhibitor use can be complicated by diabetic ketoacidosis. In untreated lipodystrophy

pancreatitis is common, yet this is due to hypertriglyceridaemia, which is likely to be improved by GLP-1 agonist use, while excessive supply of free fatty acids to the liver may promote ketogenesis. Thus assessment of both classes of drug in lipodystrophy and its genetic subgroups will be important to quantify risks and benefits, which may be distinct to those in obesity-related diabetes.

304 A further question we prespecified related to the use of rhIGF1 in people with severe 305 IR due to INSR mutations. This use of rhIGF-1 was first described in recessive INSR defects in the early 1990s ⁴², based on the rationale that IGF-1 activates a receptor and signalling 306 307 pathway very closely similar to those activated by insulin. Based on case reports, case series 308 and narrative reviews, rhIGF-1 is now commonly used in neonates with extreme IR due to 309 biallelic INSR mutations, although, unlike metreleptin in lipodystrophy, this use is still 310 unlicensed. Our review of published data is consistent with glycaemic benefits of rhIGF-1, 311 alone or in composite form with its binding protein IGFBP3, in INSR mutations. Nevertheless, such studies are challenging to interpret and are potentially fraught with bias 312 313 of different types, particularly publication bias favouring positive outcomes. Responses to 314 rhIGF1 are also challenging to determine in uncontrolled studies as small differences in 315 residual function of mutated receptors can have substantial effects on the severity and 316 natural history of the resulting IR, yet relatively few INSR mutations have been studied 317 functionally. This underlines the narrow nature of, and significant residual uncertainty in, 318 the evidence base for use of rhIGF-1 in monogenic IR.

There are several reasons why important questions about precision treatment of monogenic IR have not been settled. Although severe autosomal recessive IR is usually detected in infancy, commoner dominant forms of monogenic IR are often diagnosed relatively late, often only after years of management based on presumptive diagnoses of

323 type 2 or sometimes type 1 diabetes. Initial management as type 2 diabetes means that by 324 the time a clinical and then genetic diagnosis is made, most patents have been treated with 325 agents such as metformin, and increasingly SGLT2 inhibitors or GLP-1 agonists, outside trial 326 settings. It is not clear that harm is caused by such use of drugs with well-established safety 327 profiles and efficacy in type 2 diabetes, but the lack of systematic data gathering precludes 328 identification of specific drug-genotype interactions. Moreover, because attempts to gather 329 evidence for monogenic IR treatment has tended to focus on high-cost adjunctive therapies 330 such as metreleptin, the evidence base for their use is better developed, although controlled trials are lacking. Licensing of high-cost treatments such as metreleptin in 331 332 lipodystrophy, while effects of many more commonly used, cheaper drugs with well-333 established safety profiles lack formal testing in monogenic IR is potentially problematic, 334 skewing incentives and guidelines towards expensive therapy before optimal treatment 335 algorithms have been established.

Other challenges in conducting trials in monogenic IR arise from the exquisite sensitivity of IR to exacerbating factors such as puberty, diet, and energy balance. This creates a "signal to noise" problem particularly problematic in uncontrolled studies, in which non-pharmacological components of interventions such as increased support for behavioural change may confound attribution of beneficial outcomes to pharmacological agents tested.

The key question now is how the evidence base for managing monogenic severe IR can be improved in the face of constraints in studying rare, clinically heterogeneous, and geographically dispersed patients who are often diagnosed late with a condition that is exquisitely environmentally sensitive. Growing interest in and development of methodologies for clinical trials in rare disease ⁵⁸, including Bayesian methodologies ^{59,60},

and hybrid single- and multi-site designs ⁶¹ offer hope for future filling of evidence gaps. One 347 348 important and pragmatic opportunity arises from the development of large regional, national and international networks and registries for lipodystrophy (e.g. the Europe-based 349 350 ECLip registry ⁶²), allied to emergence of randomised registry-based trial (RRT) methodology ^{63,64}. RRTs have attracted increasing interest in several disease areas and are particularly 351 352 suitable for evaluation of agents with well-established safety profiles. When a simple 353 randomisation tool is deployed in the context of a registry, RRTs can offer rapid, cost-354 effective recruitment and high external validity (i.e. relevance to "real world" practice). In 355 monogenic IR this would permit questions to be addressed about optimal usage of different 356 "common" medications in different genetic subgroups, including the order of introduction 357 of therapies, and their optimal combinations. The guality of such studies will critically rely on good registry design and quality and completeness of data capture ^{63,64}. 358

359 In summary, severe monogenic IR syndromes are clinically and genetically 360 heterogeneous, with high early morbidity and mortality. However despite opportunities for 361 targeted therapy of some monogenic subgroups based on the nature of the causal gene 362 alteration, the evidence for genotype-stratified therapy is weak. This is in part because of 363 the rarity and frequent late diagnosis of monogenic IR, but also because therapeutic 364 research to date has focused largely on phenotypically ascertained cross cutting diagnoses 365 such as lipodystrophy. We suggest that approaches such as RRTs hold the best hope to 366 answer some of the persisting major questions about precision treatment in monogenic IR.

367

368 Authors' declaration of personal interests

R.K.S. has received speaker fees from Eli Lilly, Novo Nordisk, and Amryt. R. J. B. has received
research support from Amryt, Third Rock Ventures, Ionis, and Regeneron. K.A.P. and S.A.
report no conflicts of interest.

372

373 Acknowledgements

374 This research was funded in part, by the Wellcome Trust [Grant WT 210752 to RKS and WT 375 219606 to KAP]. For the purpose of open access, the author has applied a CCO Public 376 Domain Dedication to any Author Accepted Manuscript version arising from this submission. 377 RJB and SA are supported by the intramural research program of the National Institute of 378 Diabetes and Digestive and Kidney Diseases. The ADA/EASD Precision Diabetes Medicine 379 Initiative, within which this work was conducted, has received the following support: The 380 Covidence license was funded by Lund University (Sweden) for which technical support was 381 provided by Maria Björklund and Krister Aronsson (Faculty of Medicine Library, Lund 382 University, Sweden). Administrative support was provided by Lund University (Malmö, 383 Sweden), University of Chicago (IL, USA), and the American Diabetes Association 384 (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, Denmark) provided grant 385 support for in-person writing group meetings (PI: L Phillipson, University of Chicago, IL).

206	De	foroncos
300	Re	merences
387	1	Bonnefond, A. & Semple, R. K. Achievements, prospects and challenges in precision care for
388		monogenic insulin-deficient and insulin-resistant diabetes. <i>Diabetologia</i> 65 , 1/82-1/95 (2022).
389	2	<u>nttps://doi.org:10.100//s00125-022-05/20-7</u>
390	2	Lim, K., Haider, A., Adams, C., Sleigh, A. & Savage, D. B. Lipodistrophy: a paradigm for
391		understanding the consequences of "overloading" adipose tissue. <i>Physiol Rev</i> 101 , 907-993
392	~	(2021). <u>https://doi.org:10.1152/physrev.00032.2020</u>
393	3	Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O'Ranilly, S. Genetic syndromes of severe
394		Insulin resistance. Endocr Rev 32, 498-514 (2011). <u>https://doi.org:10.1210/er.2010-0020</u>
395	4	Gonzaga-Jauregui, C. <i>et al.</i> Clinical and Molecular Prevalence of Lipodystrophy in an
390		Unascertained Large Clinical Care Conort. <i>Didbetes</i> 69 , 249-258 (2020).
397	-	nttps://doi.org:10.233//db19-044/
398	5	Brown, R. J. <i>et al.</i> The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society
399		Practice Guideline. J Clin Endocrinol Nietab 101, 4500-4511 (2016).
400	~	<u>nttps://doi.org:10.1210/jc.2016-2466</u>
401	ю 7	29 (2013).
402	/	Agency, E. M. <i>Myalepta</i>
403		<a href="https://www.ema.europa.eu/en/medicines/numan/EPAR/myalepta#authonsation-details-
continues/2019">https://www.ema.europa.eu/en/medicines/numan/EPAR/myalepta#authonsation-details- continues/2019
404	0	<u>Section</u> > (2016). Nolan III. et al. ADA (EASD Dregision Medicing in Disbetes Initiatives An International Decensatives
405	0	and Euture Vision for Precision Medicine in Diabetes, Diabetes (are 4E , 261, 266 (2022)
400		https://doi.org/10.2227/do21.2216
407	0	<u>Intrps://doi.org.10.255//dc21-2210</u> (2021)
408	9	(2021). Study Quality Accessment Tools, shttps://www.phlbi.nih.cov/boolth.topics/study.cuality
409	10	study Quality Assessment Tools, < <u>https://www.imibr.nn.gov/nearti-topics/study-quality-</u>
410 /11	11	<u>assessment-tools</u> (Sherifali D et al Methods Canadian journal of diabetes 12 S6-S9 (2018)
411 //12	ΤΤ	https://doi.org/https://doi.org/10.1016/i.jcid.2017.10.002
413	12	Musso C Major M L Andres F & Simba V Metrelentin Treatment in Three Patients with
413	12	Generalized Linodystronby. Clinical medicine insights. Case reports 9 123-127 (2016)
415		https://doi.org/10.4137/CCRep \$40196
416	13	Beltrand L et al. Resistance to lentin-replacement therapy in Berardinelli-Sein congenital
417	13	lipodystrophy: an immunological origin. <i>Eur J Endocrinol</i> 162 , 1083-1091 (2010)
418		https://doi.org/10.1530/eie-09-1027
419	14	Vatier, C. et al. Adherence with metreleptin therapy and health self-perception in patients with
420		lipodystrophic syndromes. Orphanet I Rare Dis 14, 177 (2019) https://doi.org/10.1186/s13023-
421		019-1141-2
422	15	Beltrand, J. <i>et al.</i> Metabolic correction induced by leptin replacement treatment in young
423		children with Berardinelli-Seip congenital lipoatrophy. <i>Pediatrics</i> 120 , e291-296 (2007).
424		https://doi.org:10.1542/peds.2006-3165
425	16	Chong, A. Y., Lupsa, B. C., Cochran, E. K. & Gorden, P. Efficacy of leptin therapy in the different
426		forms of human lipodystrophy. <i>Diabetologia</i> 53, 27-35 (2010). https://doi.org:10.1007/s00125-
427		009-1502-9
428	17	Maeda, M., Maeda, T., Ebihara, K. & Ihara, K. The long-term management of congenital
429		generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese
430		siblings for approximately 20 years. Clinical pediatric endocrinology : case reports and clinical
431		investigations : official journal of the Japanese Society for Pediatric Endocrinology 28 , 139-145
432		(2019). https://doi.org:10.1297/cpe.28.139
433	18	Ebihara, K. et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of
434		leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92, 532-541
425		(2007) https://doi.org/10.1210/js.2006.1546

435 (2007). <u>https://doi.org:10.1210/jc.2006-1546</u>

436 19 Ajluni, N., Dar, M., Xu, J., Neidert, A. H. & Oral, E. A. Efficacy and Safety of Metreleptin in Patients 437 with Partial Lipodystrophy: Lessons from an Expanded Access Program. Journal of diabetes & 438 metabolism 7 (2016). https://doi.org:10.4172/2155-6156.1000659 439 20 Sekizkardes, H., Cochran, E., Malandrino, N., Garg, A. & Brown, R. J. Efficacy of Metreleptin 440 Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. J Clin 441 Endocrinol Metab 104, 3068-3076 (2019). https://doi.org:10.1210/jc.2018-02787 442 21 Simha, V. et al. Comparison of efficacy and safety of leptin replacement therapy in moderately 443 and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J 444 Clin Endocrinol Metab 97, 785-792 (2012). https://doi.org:10.1210/jc.2011-2229 445 22 Takeyari, S. et al. Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a 446 case report. Clinical pediatric endocrinology : case reports and clinical investigations : official 447 journal of the Japanese Society for Pediatric Endocrinology 28, 1-7 (2019). 448 https://doi.org:10.1297/cpe.28.1 449 23 Chaves, C., Chaves, M., Anselmo, J. & César, R. Successful long-term use of pioglitazone in 450 Berardinelli-Seip lipodystrophy-associated diabetes. Endocrinol Diabetes Metab Case Rep 2021 451 (2021). https://doi.org:10.1530/edm-20-0183 452 24 Collet-Gaudillat, C., Billon-Bancel, A. & Beressi, J. P. Long-term improvement of metabolic control 453 with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case 454 report. Diabetes Metab 35, 151-154 (2009). https://doi.org:10.1016/j.diabet.2009.01.001 455 25 Gambineri, A. et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C 456 gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol 159, 347-353 457 (2008). https://doi.org:10.1530/eje-08-0272 458 26 Moreau, F. et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a 459 case report. Diabetes Metab 33, 385-389 (2007). https://doi.org;10.1016/j.diabet.2007.04.005 460 27 Owen, K. R., Donohoe, M., Ellard, S. & Hattersley, A. T. Response to treatment with rosiglitazone 461 in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 20, 823-827 462 (2003). https://doi.org:10.1046/j.1464-5491.2003.01034.x 463 28 Simha, V., Rao, S. & Garg, A. Prolonged thiazolidinedione therapy does not reverse fat loss in 464 patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab 10, 1275-465 1276 (2008). https://doi.org:10.1111/j.1463-1326.2008.00978.x 466 29 Luedtke, A. et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA 467 mutations: a case series. Horm Metab Res 44, 306-311 (2012). https://doi.org:10.1055/s-0031-468 1301284 469 30 Agostini, M. et al. A Pharmacogenetic Approach to the Treatment of Patients With PPARG 470 Mutations. Diabetes 67, 1086-1092 (2018). https://doi.org:10.2337/db17-1236 471 31 Francis, G. A. et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian 472 kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 7, 3 (2006). 473 https://doi.org:10.1186/1471-2350-7-3 474 32 Savage, D. B. et al. Human metabolic syndrome resulting from dominant-negative mutations in 475 the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52, 910-917 476 (2003). https://doi.org:10.2337/diabetes.52.4.910 477 33 Hashimoto, N. et al. A case of type A insulin resistance associated with heterozygous Asn462Ser 478 mutation of the insulin receptor gene. Diabetology International 3, 239-243 (2012). 479 https://doi.org:10.1007/s13340-012-0079-6 480 34 Jo, W. et al. Development of endometrial carcinoma in a patient with leprechaunism (donohue 481 syndrome). Clinical pediatric endocrinology : case reports and clinical investigations : official 482 journal of the Japanese Society for Pediatric Endocrinology 22, 33-38 (2013). 483 https://doi.org:10.1292/cpe.22.33 484 35 Perge, K. et al. Intrauterine Growth Restriction and Hypertrophic Cardiomyopathy as Prenatal 485 Ultrasound Findings in a Case of Leprechaunism. Mol Syndromol 11, 223-227 (2020).

486 <u>https://doi.org:10.1159/000509837</u>

487 36 Plamper, M., Gohlke, B., Schreiner, F. & Woelfle, J. Mecasermin in Insulin Receptor-Related 488 Severe Insulin Resistance Syndromes: Case Report and Review of the Literature. International 489 journal of molecular sciences **19** (2018). https://doi.org:10.3390/ijms19051268 490 37 Carmody, D., Ladsaria, S. S., Buikema, R. K., Semple, R. K. & Greeley, S. A. Successful rhIGF1 491 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin 492 receptor mutation. Diabet Med 33, e8-e12 (2016). https://doi.org:10.1111/dme.12884 493 38 de Kerdanet, M. et al. Ten-year improvement of insulin resistance and growth with recombinant 494 human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in 495 leprechaunism. Diabetes Metab 41, 331-337 (2015). 496 https://doi.org:10.1016/j.diabet.2014.11.001 497 39 Weber, D. R., Stanescu, D. E., Semple, R., Holland, C. & Magge, S. N. Continuous subcutaneous 498 IGF-1 therapy via insulin pump in a patient with Donohue syndrome. J Pediatr Endocrinol Metab 499 27, 1237-1241 (2014). https://doi.org:10.1515/jpem-2013-0402 500 40 Regan, F. M. et al. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF 501 binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J 502 Clin Endocrinol Metab 95, 2113-2122 (2010). https://doi.org:10.1210/jc.2009-2088 503 41 Vestergaard, H., Rossen, M., Urhammer, S. A., Müller, J. & Pedersen, O. Short- and long-term 504 metabolic effects of recombinant human IGF-I treatment in patients with severe insulin 505 resistance and diabetes mellitus. Eur J Endocrinol 136, 475-482 (1997). 506 https://doi.org:10.1530/eje.0.1360475 507 42 Kuzuya, H. et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin 508 resistance syndromes. Diabetes 42, 696-705 (1993). https://doi.org:10.2337/diab.42.5.696 509 43 Metwalley, K. A. & Farghaly, H. S. Berardinelli-Seip syndrome type 1 in an Egyptian child. Indian J 510 Hum Genet 20, 75-78 (2014). https://doi.org:10.4103/0971-6866.132762 511 44 Kirel, B. et al. A case of Donohue syndrome "Leprechaunism" with a novel mutation in the insulin 512 receptor gene. Turk Pediatri Ars 52, 226-230 (2017). 513 https://doi.org:10.5152/TurkPediatriArs.2017.3193 514 45 Saito-Hakoda, A. et al. A follow-up during puberty in a Japanese girl with type A insulin resistance 515 due to a novel mutation in INSR. Clinical pediatric endocrinology : case reports and clinical 516 investigations : official journal of the Japanese Society for Pediatric Endocrinology 27, 53-57 517 (2018). https://doi.org:10.1297/cpe.27.53 518 46 Kawana, Y., Imai, J., Sawada, S., Yamada, T. & Katagiri, H. Sodium-Glucose Cotransporter 2 519 Inhibitor Improves Complications of Lipodystrophy: A Case Report. Ann Intern Med 166, 450-451 520 (2017). https://doi.org:10.7326/l16-0372 521 47 Hamaguchi, T. et al. Treatment of a case of severe insulin resistance as a result of a PIK3R1 522 mutation with a sodium-glucose cotransporter 2 inhibitor. Journal of diabetes investigation 9, 523 1224-1227 (2018). https://doi.org:10.1111/jdi.12825 524 48 Ciudin, A. et al. Successful treatment for the Dunnigan-type familial partial lipodystrophy with 525 Roux-en-Y gastric bypass. Clin Endocrinol (Oxf) 75, 403-404 (2011). 526 https://doi.org:10.1111/j.1365-2265.2011.04057.x 527 49 Grundfest-Broniatowski, S., Yan, J., Kroh, M., Kilim, H. & Stephenson, A. Successful Treatment of 528 an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass-Case Report and Literature 529 Review. J Gastrointest Surg 21, 739-743 (2017). https://doi.org:10.1007/s11605-016-3300-2 530 50 Kozusko, K. et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation 531 identified in patients with familial partial lipodystrophy. Diabetes 64, 299-310 (2015). 532 https://doi.org:10.2337/db14-0104 533 51 Kadowaki, T. et al. Two mutant alleles of the insulin receptor gene in a patient with extreme 534 insulin resistance. Science 240, 787-790 (1988). https://doi.org;10.1126/science.2834824 535 52 Yoshimasa, Y. et al. Insulin-resistant diabetes due to a point mutation that prevents insulin 536 proreceptor processing. Science 240, 784-787 (1988). https://doi.org:10.1126/science.3283938

- 537 53 Shackleton, S. et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24, 538 153-156 (2000). https://doi.org:10.1038/72807 539 54 Lightbourne, M. & Brown, R. J. Genetics of Lipodystrophy. Endocrinol Metab Clin North Am 46, 540 539-554 (2017). https://doi.org:10.1016/j.ecl.2017.01.012 541 55 Barroso, I. et al. Dominant negative mutations in human PPARgamma associated with severe 542 insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883 (1999). 543 https://doi.org:10.1038/47254 544 56 Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-545 deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586-3590 (2002). 546 https://doi.org:10.2337/diabetes.51.12.3586 547 57 Majithia, A. R. et al. Prospective functional classification of all possible missense variants in 548 PPARG. Nat Genet 48, 1570-1575 (2016). https://doi.org:10.1038/ng.3700 549 58 Mikita, J. S. et al. Determining the Suitability of Registries for Embedding Clinical Trials in the 550 United States: A Project of the Clinical Trials Transformation Initiative. Ther Innov Regul Sci 55, 6-551 18 (2021). https://doi.org:10.1007/s43441-020-00185-5 552 59 Kidwell, K. M. et al. Application of Bayesian methods to accelerate rare disease drug 553 development: scopes and hurdles. Orphanet J Rare Dis 17, 186 (2022). 554 https://doi.org:10.1186/s13023-022-02342-5 555 60 Partington, G., Cro, S., Mason, A., Phillips, R. & Cornelius, V. Design and analysis features used in 556 small population and rare disease trials: A targeted review. J Clin Epidemiol 144, 93-101 (2022). 557 https://doi.org:10.1016/j.jclinepi.2021.12.009 558 61 Adams, H. R. et al. A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an 559 ultra-rare lysosomal storage disorder. Clin Trials 16, 555-560 (2019). 560 https://doi.org:10.1177/1740774519855715 561 62 <https://www.eclip-web.org/information/registry/>(562 63 Doherty, D. A. et al. Registry randomised trials: a methodological perspective. BMJ open 13, 563 e068057 (2023). https://doi.org:10.1136/bmjopen-2022-068057 564 64 James, S., Rao, S. V. & Granger, C. B. Registry-based randomized clinical trials--a new clinical trial
- 565 paradigm. *Nat Rev Cardiol* **12**, 312-316 (2015). https://doi.org:10.1038/nrcardio.2015.33

Tables

567

568

Study types	Number of studies
Case reports	21
Non-randomised	
experimental	10
study	
Case series	8
Study Quality*	Number of studies
Good	0
Fair	15
Poor	28
Phenotypes	Number of participants
Partial	90
lipodystrophy	(72 LMNA, 15 PPARG, 2 PLIN1, 1
Generalised	56
lipodystrophy	(21 AGPAT2, 21 BSCL2, 1 PTRF,
Insulin receptor	17 (7 Monoallelic, 10 Bialle
Intervention	Number of participants
Metreleptin	111 (71/40/0)
rhIGF-1 or	
rhIGF-1/IGFBP3	15 (0/0/15)
composite	
Thiazolidinedione	13 (12/1/0)
Metformin	5 (2/1/2)
Bariatric surgery	4 (4/0/0)
SGLT2i	2 (1/1/0)

for partial lipodystrophy/generalised lipodystrophy/insulin receptor individuals respectively. Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2 inhibitor

603

598

599

600

601





Figure 2: Effects of metreleptin in monogenic forms of lipodystrophy Least square mean
 change in (A) Hemoglobin A1c (A1c), (B) Log₁₀ serum triglyceride concentration and (C) Body
 Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms
 of lipodystrophy, and subgroups with PPARG, LMNA, BSCL2, and AGPAT2 mutations.





631

632 Figure 3: Effects of recombinant human Insulin-like Growth Factor-1 (rhIGF) alone or in

633 combination with Insulin-like Growth Factor Binding Protein-3 (IGFBP3) in patients

634 with INSR mutations Least square mean change in hemoglobin A1c (A1c), in all patients

635 with *INSR* mutations, and in subgroups with biallelic and monoallelic mutations.

636

637



638

639 Figure 4: Effects of thiazolidinediones in monogenic forms of lipodystrophy Least

640 square mean change in (A) Hemoglobin A1c (A1c), (B) Log₁₀ serum triglyceride

641 concentration and (C) Body Mass Index (BMI) in patients with partial lipodystrophy,

642 generalized lipodystrophy, all forms of lipodystrophy, and subgroups with PPARG, and

643 *LMNA* mutations.

644

Supplemental Tables

Disease	Gene	Treatments
	Names and	
	Variants	
Lipodystrophy	LMNA	Medication
Severe Insulin resistance	Lamin A/C	Therapy
Type A insulin resistance	BSCL2	Medical management
Donohue syndrome	Seipin	Treatment
Rabson Mendenhall syndrome	AGPAT2	SGLT2 inhibitor
Leprechaun	PTRF	SGLT2i
Leprechaunism	CAVIN1	SGLT-2 inhibitor
FPLD	CAV1	SGLT-2i
FPLD2	ZMPSTE24	Sodium Glucose Transporter 2
		inhibitor
FPLD3	PPARG	Dapagliflozin
FPLD4	PLIN1	Empagliflozin
FPLD5	MFN2	Ertagliflozin
FPLD6	CIDEC	Canagliflozin
FPLD7	LIPE	Flozin
SHORT syndrome	PCYT1A	Thiazolidinedione
SOFT syndrome	INSR	PPARg Agonist
vSOFT	AKT2	PPAR gamma agonist
Werner syndrome	PIK3R1	TZD
Bloom syndrome	AKT2	Rosiglitazone
MOPDII	WRN	Pioglitazone
Osteodysplastic primordial dwarfism of	BLM	Troglitazone
Majewski type 2		
Alstrom syndrome	NSMCE2	GLP1RA
MANDIBULAR HYPOPLASIA, DEAFNESS,	POLD1	GLP1 Receptor Agonists
PROGEROID FEATURES, AND		
LIPODYSTROPHY SYNDROME		
MDPL	PCNT	GLP-1 Receptor Agonists
Mandibuloacral dysplasia	POC1A	GLP-1RA
MARFANOID-PROGEROID-	ALMS1	Exenatide
LIPODYSTROPHY SYNDROME		
MFLS	PSMB8	Liraglutide
PROTEASOME-ASSOCIATED	FBN1	Lixisenatide
AUTOINFLAMMATORY SYNDROME 1		
PRAAS1		Semaglutide
		Dulaglutide
		Albiglutide
		Bariatric surgery
		Obesity Surgery
		Weight reduction surgery

gastric band
Roux-en-Y
Gastric sleeve
Gastric bypass
metabolic surgery
IGF-1
rhlGF-1
somatokine
recombinant human insulin
like growth factor 1
Insulin like growth factor 1
Increlex
Mecasermin
IGF-1/IGFBP3
IGF1
rhIGF1
IGF1/IGFBP3
leptin
rhleptin
metreleptin
Myalept
Myalepta

646

647

Supplemental Table 1: Descriptors of diseases, gene names and treatments included in the initial search

650	
651	
652	
653	
654	
	Supplemental Table
655	2 Quality assessmen
656	
657	Supplemental Table 2: Detailed Quality Assessment of Included Studies
658	

659

		Treatment						
		rhIGF-1 or rhIGF-1/IGFBP3 composite	SGLT2i	TZD	Bariatric surgery	Metformin	Metreleptin	Total
	AGPAT2	0	0	0	0	1	20	21
Gene	BSCL2	0	1	1	0	0	19	21
	PTRF	0	0	0	0	0	1	1
	LMNA (progeroid)	0	0	0	0	0	2	2
	LMNA (FPL)	0	0	9	2	2	59	72
	PPARG	0	0	5	0	0	10	15
	PLIN1	0	0	0	2	0	0	2
	PIK3R1	0	1	0	0	0	0	1
	INSR	15	0	0	0	2	0	17
All partial LD			1	14	4	2	71	90
All generalised LD			1	1	0	1	40	43
All LD			2	15	4	3	111	135

660

661 Supplemental Table 3: Number of individuals by intervention and genotype in included

662 **studies** Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3,

663 insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2

664 inhibitor; TZD, thiazolidinedione; FPL = Familial Partial Lipodystrophy

665	
666	
667	
668	
669	
670	
671	
	Supplemental Table
672	4 Summary stats 14 /
673	
674	Supplemental Table 4: Summary statistics of extracted data
675	











- /10





730	
731	
732	Supplemental Figure 4: Effects of recombinant IGF-1 or IGF-1 plus
733	IGFBP3 therapy on glycated haemoglobin (A1c) in monallelic and
734	biallelic insulin receptoropathy
735	
736	
737	
738	
739	
740	
741	
742	
743	
744	
745	
746	
747	
748	
749	
750	





Supplemental Figure 5: Effects of thiazolidinedione therapy by genotype







Supplemental Figure 6: Effects of bariatric surgery by genotype

After

Before

After

Before



